ARALEN PHOSPHATE W Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Aralen Phosphate W, and when can generic versions of Aralen Phosphate W launch?
Aralen Phosphate W is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in ARALEN PHOSPHATE W is chloroquine phosphate; primaquine phosphate. There are twenty drug master file entries for this compound. Additional details are available on the chloroquine phosphate; primaquine phosphate profile page.
US Patents and Regulatory Information for ARALEN PHOSPHATE W
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE | chloroquine phosphate; primaquine phosphate | TABLET;ORAL | 014860-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Get Started Free | ⤷ Get Started Free | ⤷ Get Started Free | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
